Parnell Pharmaceuticals Holdings Ltd
PARN
PARN was delisted on the 30th of December, 2016.
20 hedge funds and large institutions have $1.17M invested in Parnell Pharmaceuticals Holdings Ltd in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 10 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
11% more funds holding
Funds holding: 18 → 20 (+2)
71% less capital invested
Capital invested by funds: $4.04M → $1.17M (-$2.87M)
90% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 10
Top Buyers
Top Sellers
PARN Hedge Fund Activity: Q4 2016 in Review
20 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Parnell Pharmaceuticals Holdings Ltd (PARN) for Q4 2016, worth a combined $1.17M — down 71% from $4.04M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PARN positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 10 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $43.9K. The largest seller was Fidelity Investments, cutting an estimated $948K.
- 20 institutional investors held Parnell Pharmaceuticals Holdings Ltd (PARN) as of Q4 2016, up from 18 in Q3 2016.
- Funds reported $1.17M of Parnell Pharmaceuticals Holdings Ltd stock for Q4 2016, down 71% quarter-over-quarter.
- 4 funds opened new Parnell Pharmaceuticals Holdings Ltd positions in Q4 2016 and 2 closed out, a net change of +2 holders.
- The largest Parnell Pharmaceuticals Holdings Ltd buyer in Q4 2016 was Susquehanna International Group, an estimated $43.9K added.
- The largest Parnell Pharmaceuticals Holdings Ltd seller in Q4 2016 was Fidelity Investments, an estimated $948K sold.
Based on aggregated 13F filings for Q4 2016.